Built on Science.
Not Marketing.
Mindtek was founded in 2017 as the first physician-led research compound supplier in Southeast Asia. Every decision since has been made in a lab, not a boardroom.
Why Mindtek Existed Before the Market Did
In 2017, serious researchers in Southeast Asia had no reliable local source for analytically verified research compounds. Import timelines, opaque supply chains, and zero testing transparency were the industry standard.
Dr. Anthony Close — active clinician, MD with dual post-graduate Masters in Molecular Biology and Biotechnology — built Mindtek to solve that gap. Not as a commercial pivot. As a clinical necessity.
We were the first. We remain the standard. The IG-era imitators that followed sell marketing. We sell data.
Dr. Anthony Close
MD · MSc · MSc · QAC
18+ years of active clinical practice in physical medicine and chronic pain management. Dual post-graduate Masters in Molecular Biology and Biotechnology. Formal Quantitative Analytical Chemistry training. Founder of one of SEA's first D2C blood-testing platforms (LabMe.ai). Owner and operator of a USP797-compliant compounding and cryogenic laboratory in Bali, Indonesia. The founder reads the spectra personally — no intermediaries between data and release decision.
Medical Doctor
18+ years clinical practice. Physical medicine & chronic pain management specialist.
Molecular Biology
Masters-level expertise applied to compound sourcing, mechanism validation, and quality assessment.
Biotechnology
Synthesis and formulation protocol design. Applied directly to Mindtek's compound preparation standards.
Quantitative Analytical Chemistry
Formal spectral interpretation training. Reads every GC-MS and HPLC output before batch release.
Compounding Standards
Operates a USP797-compliant compounding and cryogenic facility in Bali, Indonesia.
D2C Diagnostics Pioneer
Founder of LabMe.ai — one of Southeast Asia's first direct-to-consumer blood testing platforms.
The Lab Others
Cannot Replicate Overnight
Each of these capabilities took years and significant capital to build. None of them can be purchased on Instagram tomorrow.
In-House GC-MS
Gas chromatography–mass spectrometry for identity, purity, and potency verification. Every batch. No outsourcing.
In-House HPLC
High-performance liquid chromatography with ≥98% purity threshold enforced. Quantitative, not qualitative.
Cryogenic Storage
Liquid nitrogen at −196°C. Structural integrity preserved from synthesis to shipment. Temperature-logged chain of custody.
USP797 Compliant
Bali-based compounding facility built and operated to USP797 pharmaceutical compounding standards.
Batch-Level CoA
Every compound released with batch-specific Certificates of Analysis. No generic or shared CoAs.
Chain of Custody
Batch number traceable end-to-end. From synthesis lot to your facility — every step documented.
A Timeline Built on Firsts
Mindtek Founded — First in Southeast Asia
Dr. Close establishes Mindtek as the first physician-led research compound supplier in SEA. HPLC verification from day one.
Cryogenic Infrastructure Commissioned
Liquid nitrogen storage at −196°C implemented — years before competitors even discussed cold chain integrity.
USP797-Compliant Lab, Bali
Compounding facility built to pharmaceutical-grade USP797 standards. In-house GC-MS capability added.
Second in World: IV NMN & NR Protocol
Mindtek and Dripdok became the second globally to offer IV NMN and NR, and the first and only provider of hybrid IV NMN.
150+ Verified Compounds. 3 In-House Instruments.
Catalogue expands to 150+ research compounds, all batch-tested in-house. No outsourced verification.
Patient Outcomes Over ROI.
Always.
We were not built to be the largest. We were built to be the most accurate. Every compound we release is backed by data we generated ourselves — because the researchers and clinicians who use our compounds deserve nothing less.